次生代谢产物作为代谢紊乱和传染病的首选治疗方法及其代谢谱分析 - 第3部分 - Suppr

Secondary Metabolites as Treatment of Choice for Metabolic Disorders and Infectious Diseases and their Metabolic Profiling - Part 3.

作者信息

Singla Rajeev K

机构信息

Institutes for Systems Genetics Frontiers Science Center for Disease-related Molecular Network West China Hospital, Sichuan University Chengdu, 610212 Sichuan, China.

出版信息

Curr Drug Metab. 2021;22(6):412-414. doi: 10.2174/138920022206210708103019.

DOI:10.2174/138920022206210708103019

PMID:34455943

Abstract

摘要

相似文献

Secondary Metabolites as Treatment of Choice for Metabolic Disorders and Infectious Diseases and their Metabolic Profiling - Part 3.

Curr Drug Metab. 2021;22(6):412-414. doi: 10.2174/138920022206210708103019.

Secondary Metabolites as Treatment of Choice for Metabolic Disorders and Infectious Diseases and their Metabolic Profiling: Part 1.

Curr Drug Metab. 2020;21(7):480-481. doi: 10.2174/138920022107200925101631.

Secondary Metabolites as Treatment of Choice for Metabolic Disorders and Infectious Diseases & their Metabolic Profiling-Part 2.

Curr Drug Metab. 2020;21(14):1070-1071. doi: 10.2174/138920022114201230142204.

Editorial (Thematic Issue: Natural Leads in Drug Discovery against Metabolic Disorders and their Related Infectious Diseases).

Curr Top Med Chem. 2016;16(23):2523-4. doi: 10.2174/1568026616999160510121418.

Natural Products Inspired Drug Discovery for Infectious Diseases.

Med Chem. 2024;20(6):555-556. doi: 10.2174/157340642006240507100418.

Metabolomics in infectious diseases and drug discovery.

Mol Omics. 2021 Jun 14;17(3):376-393. doi: 10.1039/d1mo00017a.

Metabolomic tools used in marine natural product drug discovery.

Expert Opin Drug Discov. 2020 Apr;15(4):499-522. doi: 10.1080/17460441.2020.1722636. Epub 2020 Feb 6.

Natural Products as Clinically Important Enzyme Inhibitors.

Comb Chem High Throughput Screen. 2020;23(9):915-916. doi: 10.2174/138620732309201127105658.

Applied metabolomics in drug discovery.

Expert Opin Drug Discov. 2016 Aug;11(8):759-70. doi: 10.1080/17460441.2016.1195365. Epub 2016 Jul 1.

What role can metabolomics play in the discovery and development of new medicines for infectious diseases?

Bioanalysis. 2015;7(6):629-31. doi: 10.4155/bio.15.5.

引用本文的文献

The role of nanomaterials in enhancing natural product translational potential and modulating endoplasmic reticulum stress in the treatment of ovarian cancer.

Front Pharmacol. 2022 Oct 26;13:987088. doi: 10.3389/fphar.2022.987088. eCollection 2022.

Editorial: Exploration of Natural Product Leads for Multitarget-Based Treatment of Cancer-Computational to Experimental Journey.

Front Pharmacol. 2022 Feb 22;13:850151. doi: 10.3389/fphar.2022.850151. eCollection 2022.

Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies.

Front Pharmacol. 2022 Feb 21;13:801733. doi: 10.3389/fphar.2022.801733. eCollection 2022.

Translational Informatics for Natural Products as Antidepressant Agents.

Front Cell Dev Biol. 2022 Jan 20;9:738838. doi: 10.3389/fcell.2021.738838. eCollection 2021.

Natural Products for the Management of Castration-Resistant Prostate Cancer: Special Focus on Nanoparticles Based Studies.

Front Cell Dev Biol. 2021 Nov 5;9:745177. doi: 10.3389/fcell.2021.745177. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Secondary Metabolites as Treatment of Choice for Metabolic Disorders and Infectious Diseases and their Metabolic Profiling - Part 3.

Curr Drug Metab. 2021;22(6):412-414. doi: 10.2174/138920022206210708103019.

Secondary Metabolites as Treatment of Choice for Metabolic Disorders and Infectious Diseases and their Metabolic Profiling: Part 1.

Curr Drug Metab. 2020;21(7):480-481. doi: 10.2174/138920022107200925101631.

Secondary Metabolites as Treatment of Choice for Metabolic Disorders and Infectious Diseases & their Metabolic Profiling-Part 2.

Curr Drug Metab. 2020;21(14):1070-1071. doi: 10.2174/138920022114201230142204.

Editorial (Thematic Issue: Natural Leads in Drug Discovery against Metabolic Disorders and their Related Infectious Diseases).

Curr Top Med Chem. 2016;16(23):2523-4. doi: 10.2174/1568026616999160510121418.

Natural Products Inspired Drug Discovery for Infectious Diseases.

Med Chem. 2024;20(6):555-556. doi: 10.2174/157340642006240507100418.

Metabolomics in infectious diseases and drug discovery.

Mol Omics. 2021 Jun 14;17(3):376-393. doi: 10.1039/d1mo00017a.

Metabolomic tools used in marine natural product drug discovery.

Expert Opin Drug Discov. 2020 Apr;15(4):499-522. doi: 10.1080/17460441.2020.1722636. Epub 2020 Feb 6.

Natural Products as Clinically Important Enzyme Inhibitors.

Comb Chem High Throughput Screen. 2020;23(9):915-916. doi: 10.2174/138620732309201127105658.

Applied metabolomics in drug discovery.

Expert Opin Drug Discov. 2016 Aug;11(8):759-70. doi: 10.1080/17460441.2016.1195365. Epub 2016 Jul 1.

What role can metabolomics play in the discovery and development of new medicines for infectious diseases?

Bioanalysis. 2015;7(6):629-31. doi: 10.4155/bio.15.5.

引用本文的文献

The role of nanomaterials in enhancing natural product translational potential and modulating endoplasmic reticulum stress in the treatment of ovarian cancer.

Front Pharmacol. 2022 Oct 26;13:987088. doi: 10.3389/fphar.2022.987088. eCollection 2022.

Editorial: Exploration of Natural Product Leads for Multitarget-Based Treatment of Cancer-Computational to Experimental Journey.

Front Pharmacol. 2022 Feb 22;13:850151. doi: 10.3389/fphar.2022.850151. eCollection 2022.

Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies.

Front Pharmacol. 2022 Feb 21;13:801733. doi: 10.3389/fphar.2022.801733. eCollection 2022.

Translational Informatics for Natural Products as Antidepressant Agents.

Front Cell Dev Biol. 2022 Jan 20;9:738838. doi: 10.3389/fcell.2021.738838. eCollection 2021.

Natural Products for the Management of Castration-Resistant Prostate Cancer: Special Focus on Nanoparticles Based Studies.

Front Cell Dev Biol. 2021 Nov 5;9:745177. doi: 10.3389/fcell.2021.745177. eCollection 2021.

Secondary Metabolites as Treatment of Choice for Metabolic Disorders and Infectious Diseases and their Metabolic Profiling - Part 3.

作者信息

Singla Rajeev K

机构信息

Institutes for Systems Genetics Frontiers Science Center for Disease-related Molecular Network West China Hospital, Sichuan University Chengdu, 610212 Sichuan, China.

出版信息

Curr Drug Metab. 2021;22(6):412-414. doi: 10.2174/138920022206210708103019.

DOI:10.2174/138920022206210708103019

PMID:34455943

Abstract

摘要

Secondary Metabolites as Treatment of Choice for Metabolic Disorders and Infectious Diseases and their Metabolic Profiling - Part 3.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Secondary Metabolites as Treatment of Choice for Metabolic Disorders and Infectious Diseases and their Metabolic Profiling - Part 3.

作者信息

机构信息

出版信息